![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma patients participating in the ongoing phase 2 randomized discontinuation trial of cabozantinib.
|
| Thread Tools | |
| Display Modes | |
|
|